Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 2
2002 1
2003 1
2005 2
2007 1
2008 1
2009 1
2010 2
2011 1
2012 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Metabolomics in angiotensin II-induced cardiac hypertrophy.
Mervaala E, Biala A, Merasto S, Lempiäinen J, Mattila I, Martonen E, Eriksson O, Louhelainen M, Finckenberg P, Kaheinen P, Muller DN, Luft FC, Lapatto R, Oresic M. Mervaala E, et al. Among authors: finckenberg p. Hypertension. 2010 Feb;55(2):508-15. doi: 10.1161/HYPERTENSIONAHA.109.145490. Epub 2010 Jan 11. Hypertension. 2010. PMID: 20065148
We found great differences in the use of fatty acids as an energy source, namely, decreased levels of octanoic, oleic, and linoleic acids in dTGR (all P<0.01). The increase in cardiac hypoxanthine levels in dTGRs suggested an increase in purine degradation, whereas othe …
We found great differences in the use of fatty acids as an energy source, namely, decreased levels of octanoic, oleic, and linoleic acids in …
Discovery and characterization of ORM-11372, a novel inhibitor of the sodium-calcium exchanger with positive inotropic activity.
Otsomaa L, Levijoki J, Wohlfahrt G, Chapman H, Koivisto AP, Syrjänen K, Koskelainen T, Peltokorpi SE, Finckenberg P, Heikkilä A, Abi-Gerges N, Ghetti A, Miller PE, Page G, Mervaala E, Nagy N, Kohajda Z, Jost N, Virág L, Varró A, Papp JG. Otsomaa L, et al. Among authors: finckenberg p. Br J Pharmacol. 2020 Dec;177(24):5534-5554. doi: 10.1111/bph.15257. Epub 2020 Nov 10. Br J Pharmacol. 2020. PMID: 32959887 Free PMC article.
Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats.
Lassila M, Finckenberg P, Pere AK, Vapaatalo H, Nurminen ML. Lassila M, et al. Among authors: finckenberg p. Eur J Pharmacol. 2000 Jun 9;398(1):99-106. doi: 10.1016/s0014-2999(00)00282-x. Eur J Pharmacol. 2000. PMID: 10856453
Part of the rats were treated concomitantly either with the angiotensin converting enzyme inhibitor enalapril (30 mg kg(-1) day(-1) p.o.) or with an angiotensin AT(1) receptor antagonist valsartan (3 or 30 mg kg(-1) day(-1) p.o.). ...
Part of the rats were treated concomitantly either with the angiotensin converting enzyme inhibitor enalapril (30 mg kg(-1) day(-1) p …
Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats.
Louhelainen M, Merasto S, Finckenberg P, Vahtola E, Kaheinen P, Leskinen H, Levijoki J, Pollesello P, Haikala H, Mervaala EM. Louhelainen M, et al. Among authors: finckenberg p. J Physiol Pharmacol. 2009 Sep;60(3):41-7. J Physiol Pharmacol. 2009. PMID: 19826180 Free article.
OR-1896 prevented salt-induced cardiovascular mortality (survival rate 75 % in OR-1896 treated groups vs 38 % in untreated controls, p<0.01), ameliorated cardiac hypertrophy and improved systolic functions of the heart without major influence on systemic blood pressure. …
OR-1896 prevented salt-induced cardiovascular mortality (survival rate 75 % in OR-1896 treated groups vs 38 % in untreated controls, p …
Magnesium supplementation prevents angiotensin II-induced myocardial damage and CTGF overexpression.
Finckenberg P, Merasto S, Louhelainen M, Lindgren L, Vapaatalo H, Müller DN, Luft FC, Mervaala EM. Finckenberg P, et al. J Hypertens. 2005 Feb;23(2):375-80. doi: 10.1097/00004872-200502000-00020. J Hypertens. 2005. PMID: 15662226

Myocardial connective tissue growth factor (CTGF) mRNA and protein expressions were increased by 300% in dTGR (P < 0.05), especially in areas with myocardial infarctions and vascular inflammation. Magnesium supplementation prevented Ang II-induced myocardial CTGF overex

…

Myocardial connective tissue growth factor (CTGF) mRNA and protein expressions were increased by 300% in dTGR (P < 0.05), especial

…
Metabolomic changes in fatty liver can be modified by dietary protein and calcium during energy restriction.
Pilvi TK, Seppanen-Laakso T, Simolin H, Finckenberg P, Huotari A, Herzig KH, Korpela R, Oresic M, Mervaala EM. Pilvi TK, et al. Among authors: finckenberg p. World J Gastroenterol. 2008 Jul 28;14(28):4462-72. doi: 10.3748/wjg.14.4462. World J Gastroenterol. 2008. PMID: 18680224 Free PMC article.

RESULTS: ER on both diets significantly reduced hepatic lipid accumulation and lipid droplet size, while only whey + Ca diet significantly decreased blood glucose (P < 0.001) and serum insulin (P < 0.01). In hepatic lipid species the biggest reduction was in t

…
RESULTS: ER on both diets significantly reduced hepatic lipid accumulation and lipid droplet size, while only whey + Ca diet significantly d …
Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats.
Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML. Sipola M, et al. Among authors: finckenberg p. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):745-54. J Physiol Pharmacol. 2001. PMID: 11785770 Free article.

At the end of treatment period, SBP was 176 +/- 1 mmHg in sour milk group, 181 +/- 2 mmHg in peptide group, and 193 +/- 1 mmHg in control group (P < 0.001). After treatment withdrawal, SBP rose gradually reaching the level of control group within four weeks' follow-up.

…
At the end of treatment period, SBP was 176 +/- 1 mmHg in sour milk group, 181 +/- 2 mmHg in peptide group, and 193 +/- 1 mmHg in control gr …
Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.
Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, Haikala H, Mervaala EM. Louhelainen M, et al. Among authors: finckenberg p. Br J Pharmacol. 2007 Apr;150(7):851-61. doi: 10.1038/sj.bjp.0707157. Epub 2007 Feb 26. Br J Pharmacol. 2007. PMID: 17325658 Free PMC article.
Levosimendan improved survival (survival rates in low- and high-dose levosimendan groups 12/12 and 9/12, p<0.001 and p=0.05, respectively), increased cardiac function, and ameliorated cardiac hypertrophy. ...
Levosimendan improved survival (survival rates in low- and high-dose levosimendan groups 12/12 and 9/12, p<0.001 and p=0.05 …
16 results